Affimed N.V. Company Profile (NASDAQ:AFMD)

About Affimed N.V. (NASDAQ:AFMD)

Affimed N.V. logoAffimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AFMD
  • CUSIP: N/A
  • Web:
  • Market Cap: $92.27 million
  • Outstanding Shares: 43,938,000
Average Prices:
  • 50 Day Moving Avg: $2.09
  • 200 Day Moving Avg: $2.24
  • 52 Week Range: $1.65 - $3.19
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.99 million
  • Price / Sales: 23.13
  • Book Value: $1.10 per share
  • Price / Book: 1.91
  • EBIDTA: ($36,260,000.00)
  • Net Margins: -978.31%
  • Return on Equity: -73.85%
  • Return on Assets: -59.02%
  • Debt-to-Equity Ratio: 0.13%
  • Current Ratio: 6.69%
  • Quick Ratio: 6.65%
  • Average Volume: 244,594 shs.
  • Beta: 3.61
  • Short Ratio: 2.6

Frequently Asked Questions for Affimed N.V. (NASDAQ:AFMD)

What is Affimed N.V.'s stock symbol?

Affimed N.V. trades on the NASDAQ under the ticker symbol "AFMD."

How were Affimed N.V.'s earnings last quarter?

Affimed N.V. (NASDAQ:AFMD) announced its earnings results on Thursday, August, 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.02. The firm had revenue of $0.51 million for the quarter, compared to analyst estimates of $1.31 million. Affimed N.V. had a negative net margin of 978.31% and a negative return on equity of 73.85%. Affimed N.V.'s revenue was down 75.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.24) earnings per share. View Affimed N.V.'s Earnings History.

When will Affimed N.V. make its next earnings announcement?

Affimed N.V. is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Affimed N.V..

Where is Affimed N.V.'s stock going? Where will Affimed N.V.'s stock price be in 2017?

4 equities research analysts have issued twelve-month target prices for Affimed N.V.'s shares. Their forecasts range from $2.00 to $10.00. On average, they anticipate Affimed N.V.'s stock price to reach $5.38 in the next twelve months. View Analyst Ratings for Affimed N.V..

Who are some of Affimed N.V.'s key competitors?

Who owns Affimed N.V. stock?

Affimed N.V.'s stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (8.85%), Bain Capital Public Equity Management LLC (7.30%), Tekla Capital Management LLC (3.20%), Nationwide Fund Advisors (1.15%), California Public Employees Retirement System (0.40%) and DAFNA Capital Management LLC (0.21%). View Institutional Ownership Trends for Affimed N.V..

Who bought Affimed N.V. stock? Who is buying Affimed N.V. stock?

Affimed N.V.'s stock was bought by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC, Nationwide Fund Advisors and Creative Planning. View Insider Buying and Selling for Affimed N.V..

How do I buy Affimed N.V. stock?

Shares of Affimed N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Affimed N.V.'s stock price today?

One share of Affimed N.V. stock can currently be purchased for approximately $2.10.

MarketBeat Community Rating for Affimed N.V. (NASDAQ AFMD)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  211
MarketBeat's community ratings are surveys of what our community members think about Affimed N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Affimed N.V. (NASDAQ:AFMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $5.38 (155.95% upside)

Analysts' Ratings History for Affimed N.V. (NASDAQ:AFMD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Jefferies Group LLCReiterated RatingHold$2.50LowView Rating Details
7/13/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$7.00HighView Rating Details
5/18/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$10.00LowView Rating Details
11/3/2016Leerink SwannReiterated RatingHold$2.00N/AView Rating Details
5/18/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$7.00N/AView Rating Details
12/10/2015LaidlawInitiated CoverageBuy$15.00N/AView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for Affimed N.V. (NASDAQ:AFMD)
Earnings by Quarter for Affimed N.V. (NASDAQ:AFMD)
Earnings History by Quarter for Affimed N.V. (NASDAQ AFMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/20176/30/2017($0.22)($0.20)$1.31 million$0.51 millionViewListenView Earnings Details
5/17/20173/31/2017($0.24)($0.21)$1.73 million$1.94 millionViewN/AView Earnings Details
3/30/201712/31/2016($0.31)($0.17)$1.20 million$1.37 millionViewN/AView Earnings Details
11/2/2016Q316($0.26)($0.31)$2.65 million$0.94 millionViewN/AView Earnings Details
8/10/2016Q216($0.22)($0.24)$2.10 million$2.07 millionViewListenView Earnings Details
5/18/2016Q116($0.15)($0.25)$1.88 million$1.90 millionViewListenView Earnings Details
3/30/2016Q415($0.18)($0.19)$1.71 million$1.66 millionViewListenView Earnings Details
11/10/2015Q315($0.25)($0.27)$1.87 million$1.20 millionViewListenView Earnings Details
8/4/2015Q215($0.14)($0.21)$2.56 million$2.21 millionViewN/AView Earnings Details
5/21/2015Q115($0.14)($0.07)$4.75 million$2.82 millionViewListenView Earnings Details
3/25/2015Q414($0.39)($0.24)$0.89 million$0.09 millionViewN/AView Earnings Details
11/18/2014Q314($0.33)$2.69$0.89 million$2.35 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Affimed N.V. (NASDAQ:AFMD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.21)($0.18)($0.20)
Q3 20174($0.22)($0.19)($0.20)
Q4 20173($0.24)($0.18)($0.21)
(Data provided by Zacks Investment Research)


Dividend History for Affimed N.V. (NASDAQ:AFMD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Affimed N.V. (NASDAQ:AFMD)
No insider trades for this company have been tracked by


Headline Trends for Affimed N.V. (NASDAQ:AFMD)
Latest Headlines for Affimed N.V. (NASDAQ:AFMD)
DateHeadline logoAffimed to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology - September 22 at 2:57 PM logoAffimed (AFMD) Names Dr. Wolfgang Fischer as Chief Operating Officer - September 13 at 4:29 PM logoNew operating chief at Affimed - September 13 at 4:29 PM logoWhat Is Affimed NV’s (AFMD) Share Price Doing? - September 13 at 4:29 PM logoAffimed Appoints Dr. Wolfgang Fischer as Chief Operating Officer - September 13 at 5:56 AM logoAffimed N.V. (AFMD) Expected to Post Quarterly Sales of $970,000.00 - September 12 at 9:18 AM logoAffimed N.V. (AFMD) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow - September 8 at 3:56 PM logoAffimed NV :AFMD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017 - September 6 at 3:31 PM logoValuEngine Lowers Affimed N.V. (AFMD) to Strong Sell - September 3 at 11:22 PM logoAffimed N.V. (AFMD) Receives Average Rating of "Hold" from Brokerages - September 1 at 2:44 AM logo Analysts Expect Affimed N.V. (AFMD) Will Post Quarterly Sales of $970,000.00 - August 24 at 2:56 AM logoAffimed N.V. (NASDAQ:AFMD) Given Consensus Recommendation of "Hold" by Brokerages - August 7 at 8:06 AM logo Brokerages Expect Affimed N.V. (AFMD) Will Announce Quarterly Sales of $970,000.00 - August 6 at 7:12 AM logo-$0.21 Earnings Per Share Expected for Affimed N.V. (NASDAQ:AFMD) This Quarter - August 4 at 2:26 PM logoFY2017 Earnings Forecast for Affimed N.V. Issued By Jefferies Group (AFMD) - August 4 at 11:54 AM logoOppenheimer Holdings Comments on Affimed N.V.'s Q3 2017 Earnings (AFMD) - August 4 at 8:48 AM logoAffimed N.V. (NASDAQ:AFMD) to Post Q3 2017 Earnings of ($0.20) Per Share, Leerink Swann Forecasts - August 4 at 8:48 AM logoQ3 2017 Earnings Forecast for Affimed N.V. Issued By SunTrust Banks (AFMD) - August 3 at 8:48 AM logoAffimed N.V. (AFMD) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - August 2 at 2:24 PM logoEdited Transcript of AFMD earnings conference call or presentation 1-Aug-17 12:30pm GMT - August 2 at 2:40 AM logoAffimed Reports Financial Results for Second Quarter 2017 - August 1 at 4:36 PM logoAffimed N.V. (AFMD) Earns "Hold" Rating from Jefferies Group LLC - July 27 at 6:50 PM logoAffimed N.V. (NASDAQ:AFMD) Scheduled to Post Earnings on Thursday - July 27 at 7:02 AM logoSunTrust Banks, Inc. Initiates Coverage on Affimed N.V. (NASDAQ:AFMD) - July 16 at 5:14 PM logo$1.42 Million in Sales Expected for Affimed N.V. (AFMD) This Quarter - July 15 at 9:20 AM logoAffimed N.V. (AFMD) Given Average Rating of "Hold" by Analysts - July 13 at 10:23 PM logo-$0.22 Earnings Per Share Expected for Affimed N.V. (AFMD) This Quarter - July 13 at 8:28 AM logoAffimed (AFMD) Looks Good: Stock Moves Up 8.7% in Session - July 10 at 3:16 PM logoAffimed N.V. (NASDAQ:AFMD) Upgraded by ValuEngine to "Sell" - July 1 at 10:04 AM logoAffimed Presents Preclinical Data on AFM24 and AFM26 at EACR-AACR-SIC 2017 - June 27 at 6:28 AM logoZacks: Analysts Expect Affimed N.V. (AFMD) Will Post Earnings of -$0.22 Per Share - June 19 at 8:16 AM logoAffimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017 - June 6 at 9:46 AM logoResearch Analysts Offer Predictions for Affimed NV's Q2 2017 Earnings (AFMD) - May 22 at 7:18 AM logoQ2 2017 EPS Estimates for Affimed NV (AFMD) Lowered by Leerink Swann - May 22 at 7:18 AM logoQ3 2017 EPS Estimates for Affimed NV (AFMD) Reduced by Analyst - May 22 at 7:18 AM logoOppenheimer Holdings Inc. Analysts Give Affimed NV (AFMD) a $10.00 Price Target - May 19 at 5:54 PM logoAffimed NV (AFMD) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS - May 19 at 12:50 AM logoAffimed to Present Immune Cell Engager Data at ASCO Annual Meeting and EACR-AACR-SIC Special Conference - May 17 at 8:26 PM logoAffimed Announces First Quarter 2017 Financial Results and Corporate Update Conference Call - May 10 at 9:28 AM logoAffimed NV (AFMD) Earns Coverage Optimism Rating of 0.23 - May 4 at 7:54 AM logoAffimed NV (AFMD) Downgraded to "Hold" at Zacks Investment Research - May 4 at 1:04 AM logoAffimed NV (AFMD) Expected to Announce Quarterly Sales of $1.79 Million - May 3 at 4:38 PM logoAffimed NV (AFMD) Stock Rating Upgraded by Zacks Investment Research - May 3 at 12:22 AM logoAffimed NV (AFMD) Getting Somewhat Favorable Media Coverage, Study Shows - May 1 at 11:41 AM logoAffimed NV (AFMD) Expected to Announce Earnings of -$0.27 Per Share - May 1 at 10:06 AM logoAffimed NV (AFMD) Earning Somewhat Positive Press Coverage, Analysis Finds - April 27 at 9:34 AM logoAffimed NV (AFMD) Stock Rating Reaffirmed by Jefferies Group LLC - April 26 at 6:46 PM logoAffimed NV (AFMD) Receives Media Impact Rating of 0.56 - April 24 at 12:10 PM logoZacks Investment Research Lowers Affimed NV (AFMD) to Hold - April 21 at 9:46 PM logoAffimed NV (AFMD) Earns Media Impact Score of 0.40 - April 20 at 10:45 AM



Affimed N.V. (AFMD) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff